However, those plasma-purified or recombinant preparations of the physiological regulator C1 esterase inhibitor (C1-INH) are not complement-specific and also block proteases of the coagulation and kinin system, and are thus-far only approved for a disease with no major complement involvement (i.e., hereditary angioedema) [101]. The gene discussed is SERPING1; the disease is hereditary angioedema.